PATH commissioned this report in an effort to evaluate whether dose-sparing, possibly through the intradermal (ID) route, could improve the availability of yellow fever vaccine globally. The authors identify and discuss potential benefits, possible obstacles, and associated costs of dose-sparing as a vaccine delivery strategy. In addition, the report includes an assessment of which settings would be most appropriate and to what extent novel ID delivery devices, such as needle-free disposable-syringe jet injectors, would help to facilitate its successful implementation.
Author(s): Hickling J, Jones R
Corporate author(s): Working in Tandem, PATH
Publication date: April 2013
2,035 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA